1. Home
  2. CGEM vs CHY Comparison

CGEM vs CHY Comparison

Compare CGEM & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.58

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

HOLD

Current Price

$12.87

Market Cap

896.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
CHY
Founded
2016
2003
Country
United States
United States
Employees
109
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
896.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
CHY
Price
$14.58
$12.87
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$30.13
N/A
AVG Volume (30 Days)
713.9K
205.0K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
10.11%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$10.20
52 Week High
$16.74
$12.91

Technical Indicators

Market Signals
Indicator
CGEM
CHY
Relative Strength Index (RSI) 54.60 70.74
Support Level $11.92 $11.19
Resistance Level $15.66 N/A
Average True Range (ATR) 0.98 0.17
MACD 0.13 0.05
Stochastic Oscillator 62.78 91.46

Price Performance

Historical Comparison
CGEM
CHY

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

Share on Social Networks: